Can You Have Weight Loss Injections with Heart Failure?

Step 1: identifying which type of heart failure you have

Heart failure is not a single condition. The two main categories, heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), carry different evidence bases when it comes to GLP-1 medicines. In HFpEF, where obesity is a particularly common driver, the STEP-HFpEF trial found that semaglutide 2.4mg produced meaningful improvements in symptoms, exercise capacity and body weight compared with placebo in people with this form of the condition. That trial data is now part of the conversation a prescriber would have with someone in that situation. For HFrEF, the picture is less settled, and an earlier trial of liraglutide (a different GLP-1) raised a caution about increased hospitalisations in that specific group, which means prescribers approach reduced-ejection-fraction heart failure with additional care. Understanding your classification, usually from your cardiologist's letters or your NHS Summary Care Record, is the first thing any responsible clinical assessment needs to establish. If you want a fuller picture of how cardiac conditions interact with these medicines, the weight loss injections and heart disease page covers the broader cardiovascular landscape.

Step 2: assessing severity, stability and your current cardiac medicines

Even within a single heart-failure category, severity changes the picture. Someone with well-compensated, stable, mild heart failure managed on standard medication is in a very different clinical position from someone with decompensated or advanced disease. A prescriber will want to know how your condition is currently controlled, which cardiac medicines you take, and whether your situation is stable enough for a new treatment to be introduced safely. Certain medicines commonly prescribed for heart failure, such as diuretics, can interact with the gastrointestinal side effects of GLP-1 injections: if vomiting or diarrhoea occur in the early weeks, dehydration can be a risk that affects kidney function and cardiac load. That is why the clinical review before starting treatment matters as much as the prescription itself. You can read more about the general eligibility framework that prescribers apply on the who can have weight loss injections page, which sets out the licensed criteria alongside the kinds of health history that prompt extra scrutiny. NHS England's guidance on weight management injections, available on the NHS England weight management injections page, also covers the role of wraparound clinical support for people with complex health backgrounds.

Step 3: weighing the cardiac risk of staying at your current weight

This is where the conversation becomes genuinely two-sided. Obesity is itself a major driver of worsening heart failure, particularly HFpEF. Elevated body weight increases cardiac workload, worsens breathlessness, and is linked to higher rates of hospitalisation in heart-failure populations. For some people, the cardiovascular risk of continuing at their current weight is meaningfully higher than the risk associated with a carefully supervised weight-loss programme. A prescriber considering this question is not just asking whether the medicine is safe; they are asking whether the condition it treats poses a risk that outweighs the medicine's known cautions. We know this can feel like a frustrating calculation to be told about rather than given a straight yes or no. The truth is that the evidence genuinely varies by individual, which is precisely why a clinician reviews the full picture rather than applying a single rule. General information about the weight loss injection options licensed in the UK, and the conditions they target, is a useful starting point before a consultation. If you are curious about the cost dimension of private treatment, the how much are weight loss injections page covers what the price of a legitimate, clinician-led private service typically includes.

Step 4: what happens at a nume consultation if you have heart failure

At nume, your consultation questionnaire asks about pre-existing cardiovascular conditions including heart failure, your current medications, and your cardiac history. That information goes to a GPhC-registered Independent Prescriber the same day, not to an automated system. The prescriber may ask for supporting documentation, such as a recent clinic letter from your cardiologist, before making a decision; for more complex cardiac histories this is standard practice, not an obstacle. We also notify your GP as part of the assessment, in line with GPhC guidance, so your cardiac care team remains in the loop. Our clinical team, led by our clinical director, sets the protocols that govern how these decisions are made. If the prescriber concludes that treatment is not appropriate at this stage, they will tell you clearly and explain why. If treatment is approved, the same-day dispatch and free next-working-day delivery via DPD means your first pen arrives quickly and discreetly. You can explore the full range of weight loss injections we offer, and read about related eligibility questions, including those specific to weight loss injections and heart conditions more broadly, before deciding whether to proceed. The can I have weight loss injections page is also worth reading if you want a comprehensive overview of the assessment criteria. The NHS overview of tirzepatide, available via the NHS medicines page for tirzepatide, lists the full set of conditions and medicines that a prescriber must consider before issuing a prescription. If you have reviewed the information here and feel a consultation is the right next step, our prescribers are ready to assess your case properly.